Search

Your search keyword '"Harris, John E."' showing total 658 results
Start Over Author "Harris, John E."
658 results on '"Harris, John E."'

52. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial

Author

Hamzavi, Iltefat, primary, Rosmarin, David, additional, Harris, John E., additional, Pandya, Amit G., additional, Lebwohl, Mark, additional, Gottlieb, Alice B., additional, Butler, Kathleen, additional, Kuo, Fiona I., additional, Sun, Kang, additional, and Grimes, Pearl, additional

Published
2022
Full Text
View/download PDF

56. Systemic therapies in vitiligo: a review.

Author

Fatima, Sakeena, Abbas, Tazeen, Refat, Maggi A., Harris, John E., Lim, Henry W., Hamzavi, Iltefat H., and Mohammad, Tasneem F.

Subjects
VITILIGO, BODY surface area, MACULES, IMMUNOSUPPRESSIVE agents
Abstract

Vitiligo is characterized by the development of depigmented macules and patches. Autoimmunity has been established as a factor in disease pathogenesis, leading to utilization of immunosuppressive agents. Topical immunosuppressants are commonly used; however, this treatment modality is often cumbersome and inefficient, as many patients have active disease with extensive body surface area involvement. Prompt and aggressive treatment of vitiligo is important, as this may prevent progression and improve quality of life. To meet these challenges and improve patient outcomes, interest in systemic therapies has grown. Currently, oral therapies are rarely prescribed, likely due to concerns with systemic side effects and unclear efficacy. This article provides a brief overview on the use of systemic agents in treating vitiligo in order to provide additional therapeutic options to clinicians. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

58. Systemic therapies in vitiligo: a review

Author

Fatima, Sakeena, primary, Abbas, Tazeen, additional, Refat, Maggi A., additional, Harris, John E., additional, Lim, Henry W., additional, Hamzavi, Iltefat H., additional, and Mohammad, Tasneem F., additional

Published
2022
Full Text
View/download PDF

70. scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in T reg function

Author

Gellatly, Kyle J., primary, Strassner, James P., additional, Essien, Kingsley, additional, Refat, Maggi Ahmed, additional, Murphy, Rachel L., additional, Coffin-Schmitt, Anthony, additional, Pandya, Amit G., additional, Tovar-Garza, Andrea, additional, Frisoli, Michael L., additional, Fan, Xueli, additional, Ding, Xiaolan, additional, Kim, Evangeline E., additional, Abbas, Zainab, additional, McDonel, Patrick, additional, Garber, Manuel, additional, and Harris, John E., additional

Published
2021
Full Text
View/download PDF

78. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma

Author

Fukuda, Keitaro, primary, Okamura, Ken, additional, Riding, Rebecca L., additional, Fan, Xueli, additional, Afshari, Khashayar, additional, Haddadi, Nazgol-Sadat, additional, McCauley, Sean M., additional, Guney, Mehmet H., additional, Luban, Jeremy, additional, Funakoshi, Takeru, additional, Yaguchi, Tomonori, additional, Kawakami, Yutaka, additional, Khvorova, Anastasia, additional, Fitzgerald, Katherine A., additional, and Harris, John E., additional

Published
2021
Full Text
View/download PDF

79. Editorial: Immunology of Vitiligo

Author

Seneschal, Julien, primary, Harris, John E., additional, Le Poole, I. Caroline, additional, Passeron, Thierry, additional, Speeckaert, Reinhart, additional, and Boniface, Katia, additional

Published
2021
Full Text
View/download PDF

85. Efficacy and safety of upadacitinib in a phase 2 randomized, double-blind, dose-ranging study of adults with extensive non-segmental vitiligo.

Author

Passeron, Thierry, Ezzedine, Khaled, Hamzavi, Iltefat, van Geel, Nanja, Schlosser, Bethanee J., Xiaofei Hu, Xiaohong Huang, Rosmarin, David, Harris, John E., Camp, Heidi S., and Pandya, Amit G.

Subjects
VITILIGO, OPPORTUNISTIC infections, THROMBOEMBOLISM, ADULTS, ISCHEMIC stroke
Abstract

Introduction & Objectives: Janus kinase (JAK) inhibition is a promising approach for the treatment of vitiligo. Here, we report the clinical efficacy and safety of upadacitinib (UPA), an oral JAK inhibitor, in a phase 2b multicenter, randomized, double-blind, placebo-controlled study of adults with extensive non-segmental vitiligo (NSV). Materials & Methods: Eligible patients were aged 18-65 years with NSV, a Facial Vitiligo Area Scoring Index (F-VASI) of ≥0.5, and a Total Vitiligo Area Scoring Index (T-VASI) of ≥5 at baseline. This 52-week study (NCT04927975) comprised 2 periods. In period 1, patients were randomly assigned to once daily UPA 22 mg (UPA22), UPA 11 mg (UPA11), UPA 6 mg (UPA6), or placebo (PBO) for 24 weeks of treatment. In a 28-week blinded extension (period 2), patients receiving UPA during period 1 continued their respective regimens; patients who received PBO in period 1 were pre-assigned to either UPA11 or UPA22. Clinical efficacy endpoints evaluated through week 36 included percent change from baseline (%CFB) in F-VASI (week 24, primary endpoint), reductions from baseline in F-VASI of ≥50% (F-VASI 50) and ≥75% (F-VASI 75), %CFB in T-VASI, and reduction from baseline in T-VASI of ≥50% (T-VASI 50). Safety data as of January 13, 2023 (data cutoff date) are presented. Results: Of the 185 patients enrolled in period 1, 165 (89.2%) continued to period 2. At baseline, 68% of patients had extensive vitiligo (T-VASI > 10), and 71% had active vitiligo. At week 24, the %CFB in F-VASI was greater with UPA11 (-35.6%) and UPA22 (-34.0%) vs PBO (-14.4%; nominal P = .005 and P = .013, respectively). A greater proportion of patients achieved F-VASI 50 and F-VASI 75 with UPA11 (38.3%, 19.1%) and UPA22 (39.5%, 14.0%) vs PBO (10.9%, 2.2%; nominal P < .05 for both doses and for both endpoints). Likewise, the %CFB in T-VASI was greater with UPA11 (-17.3%) and UPA22 (-20.7%) vs PBO (-6.4%; nominal P = .026 and P = .005, respectively). A higher percentage of patients achieved T-VASI 50 with UPA22 (11.6%) than with PBO (2.2%; nominal P = .027). UPA efficacy continued to improve through week 36, with %CFB in F-VASI for UPA6, UPA11, and UPA22 of -20.8%, -44.9% and -47.7%, respectively. At week 36, F-VASI 50 was achieved with UPA6, UPA11, and UPA22 by 34.2%, 54.3% and 61.5% of patients and F-VASI 75 by 15.8%, 40.0%, and 30.8%, respectively. At week 36, %CFB in T-VASI for UPA6, UPA11 and UPA22 were -24.3%, -32.0% and -37.6%, with 10.5%, 20.0% and 19.2% of patients, respectively, achieving T-VASI 50. Treatment-emergent adverse event (TEAE) rates were generally similar with UPA and PBO in period 1 (most common TEAEs: COVID-19, acne, fatigue, and headache) and were similar across treatment arms in period 2. One death adjudicated as undetermined/unknown cause and deemed by the investigator to have no reasonable possibility of being related to study drug occurred in the UPA22 group (period 1). One adjudicated event of nonfatal ischemic stroke occurred with UPA11 (period 2). There were no adjudicated events of venous thromboembolism, gastrointestinal perforation, or events of opportunistic infection, active tuberculosis, or malignancy. Conclusion: Treatment with UPA for 24 weeks resulted in greater improvements vs PBO in the clinical outcomes of adults with extensive NSV. Observed clinical efficacy continued to improve through week 36 with UPA treatment. UPA was generally well tolerated, with no new safety signals identified. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

90. Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications

Author

van Geel, Nanja, primary, Hamzavi, Iltefat, additional, Kohli, Indermeet, additional, Wolkerstorfer, Albert, additional, Lim, Henry W., additional, Bae, Jung Min, additional, Lui, Harvey, additional, Harris, John E., additional, Pandya, Amit G., additional, Thng Tien Guan, Steven, additional, Abdallah, Marwa, additional, Esmat, Samia, additional, Seneschal, Julien, additional, Speeckaert, Reinhart, additional, Grine, Lynda, additional, Kang, Hee Young, additional, Raboobee, Noufal, additional, Xiang, Leihong Flora, additional, Bekkenk, Marcel, additional, Picardo, Mauro, additional, and Taieb, Alain, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results